

1. Participants with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
2. IHC Her2 陰性
3. 此試驗藥物需為復發或轉移病人第一線。
4. 若有 adjuvant therapy, 治療完成需離收案至少間隔 6 個月以上。
5. 病灶需符合 RECIST 1.1 可測量之病灶。


Clinical Study Protocol - 1.0
Master Protocol Study - D7986C00001

AstraZeneca

1.2 Schema

The general study design is summarised in Figure 1.

Figure 1 Study Design



* Details about discontinuation criteria are provided in Section 7.1.

Substudies may be opened sequentially or in parallel.

FOLFOX 5-fluorouracil, oxaliplatin, and leucovorin; GEJ gastroesophageal junction; XELOX capecitabine and oxaliplatin.